Cargando…
Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact
Remdesivir and dexamethasone are the only drugs providing reductions in the lengths of hospital stays for COVID-19 patients. We assessed the impacts of remdesivir on hospital-bed resources and budgets affected by the COVID-19 outbreak. A stochastic agent-based model was combined with epidemiological...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754316/ https://www.ncbi.nlm.nih.gov/pubmed/35020746 http://dx.doi.org/10.1371/journal.pone.0262462 |
_version_ | 1784632247346790400 |
---|---|
author | Béraud, Guillaume Timsit, Jean-François Leleu, Henri |
author_facet | Béraud, Guillaume Timsit, Jean-François Leleu, Henri |
author_sort | Béraud, Guillaume |
collection | PubMed |
description | Remdesivir and dexamethasone are the only drugs providing reductions in the lengths of hospital stays for COVID-19 patients. We assessed the impacts of remdesivir on hospital-bed resources and budgets affected by the COVID-19 outbreak. A stochastic agent-based model was combined with epidemiological data available on the COVID-19 outbreak in France and data from two randomized control trials. Strategies involving treating with remdesivir only patients with low-flow oxygen and patients with low-flow and high-flow oxygen were examined. Treating all eligible low-flow oxygen patients during the entirety of the second wave would have decreased hospital-bed occupancy in conventional wards by 4% [2%; 7%] and intensive care unit (ICU)-bed occupancy by 9% [6%; 13%]. Extending remdesivir use to high-flow-oxygen patients would have amplified reductions in ICU-bed occupancy by up to 14% [18%; 11%]. A minimum remdesivir uptake of 20% was required to observe decreases in bed occupancy. Dexamethasone had effects of similar amplitude. Depending on the treatment strategy, using remdesivir would, in most cases, generate savings (up to 722€) or at least be cost neutral (an extra cost of 34€). Treating eligible patients could significantly limit the saturation of hospital capacities, particularly in ICUs. The generated savings would exceed the costs of medications. |
format | Online Article Text |
id | pubmed-8754316 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-87543162022-01-13 Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact Béraud, Guillaume Timsit, Jean-François Leleu, Henri PLoS One Research Article Remdesivir and dexamethasone are the only drugs providing reductions in the lengths of hospital stays for COVID-19 patients. We assessed the impacts of remdesivir on hospital-bed resources and budgets affected by the COVID-19 outbreak. A stochastic agent-based model was combined with epidemiological data available on the COVID-19 outbreak in France and data from two randomized control trials. Strategies involving treating with remdesivir only patients with low-flow oxygen and patients with low-flow and high-flow oxygen were examined. Treating all eligible low-flow oxygen patients during the entirety of the second wave would have decreased hospital-bed occupancy in conventional wards by 4% [2%; 7%] and intensive care unit (ICU)-bed occupancy by 9% [6%; 13%]. Extending remdesivir use to high-flow-oxygen patients would have amplified reductions in ICU-bed occupancy by up to 14% [18%; 11%]. A minimum remdesivir uptake of 20% was required to observe decreases in bed occupancy. Dexamethasone had effects of similar amplitude. Depending on the treatment strategy, using remdesivir would, in most cases, generate savings (up to 722€) or at least be cost neutral (an extra cost of 34€). Treating eligible patients could significantly limit the saturation of hospital capacities, particularly in ICUs. The generated savings would exceed the costs of medications. Public Library of Science 2022-01-12 /pmc/articles/PMC8754316/ /pubmed/35020746 http://dx.doi.org/10.1371/journal.pone.0262462 Text en © 2022 Béraud et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Béraud, Guillaume Timsit, Jean-François Leleu, Henri Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact |
title | Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact |
title_full | Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact |
title_fullStr | Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact |
title_full_unstemmed | Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact |
title_short | Remdesivir and dexamethasone as tools to relieve hospital care systems stressed by COVID-19: A modelling study on bed resources and budget impact |
title_sort | remdesivir and dexamethasone as tools to relieve hospital care systems stressed by covid-19: a modelling study on bed resources and budget impact |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8754316/ https://www.ncbi.nlm.nih.gov/pubmed/35020746 http://dx.doi.org/10.1371/journal.pone.0262462 |
work_keys_str_mv | AT beraudguillaume remdesiviranddexamethasoneastoolstorelievehospitalcaresystemsstressedbycovid19amodellingstudyonbedresourcesandbudgetimpact AT timsitjeanfrancois remdesiviranddexamethasoneastoolstorelievehospitalcaresystemsstressedbycovid19amodellingstudyonbedresourcesandbudgetimpact AT leleuhenri remdesiviranddexamethasoneastoolstorelievehospitalcaresystemsstressedbycovid19amodellingstudyonbedresourcesandbudgetimpact |